002550 千红制药
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)14.54814.3207.41514.1308.608
总资产报酬率 ROA (%)13.11112.7236.52812.1717.301
投入资产回报率 ROIC (%)14.43114.0287.13813.4548.285

边际利润分析
销售毛利率 (%)57.71354.85243.26538.59144.462
营业利润率 (%)36.06125.97211.26415.62811.165
息税前利润/营业总收入 (%)36.01625.13710.86612.42211.465
净利润/营业总收入 (%)30.29921.8309.84813.8889.939

收益指标分析
经营活动净收益/利润总额(%)67.64174.14472.82986.68070.290
价值变动净收益/利润总额(%)3.0243.5094.312-1.2730.306
营业外收支净额/利润总额(%)-0.079-0.139-0.4090.0900.019

偿债能力分析
流动比率 (X)11.8357.5827.9006.0655.298
速动比率 (X)9.4955.6714.9754.1363.946
资产负债率 (%)8.48511.08910.56313.27615.557
带息债务/全部投入资本 (%)-3.011-2.225-0.6541.0240.704
股东权益/带息债务 (%)-3,310.007-4,435.120-14,863.1289,308.95713,501.109
股东权益/负债合计 (%)1,075.132802.064840.232657.760545.117
利息保障倍数 (X)-2,158.509-31.468-30.840-3.85738.525

营运能力分析
应收账款周转天数 (天)55.95656.54178.39075.07875.332
存货周转天数 (天)212.773268.752199.089119.244123.871